Wells Fargo analyst Jim Birchenough raised the firm’s price target on Arcturus Therapeutics (ARCT) to $45 from $35 and keeps an Overweight rating on the shares. Following review of data from the Japan booster study, the firm points out on a research note on Friday that ARCT-154 demonstrates superiority over Pfizer’s (PFE) COMIRNATY, which in its opinion establishes Arcturus’ mRNA vaccine platform as a strong contender with differentiation in longer durability.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on ARCT: